Gastric emptying of orally administered glucose solutions and incretin hormone responses are unaffected by laparoscopic adjustable gastric banding

Lotte Usinger; Katrine B Hansen; Viggo B Kristiansen; Steen Larsen; Jens Juul Holst; Filip K Knop

doi:10.1007/s11695-011-0362-9

Gastric emptying of orally administered glucose solutions and incretin hormone responses are unaffected by laparoscopic adjustable gastric banding

Lotte Usinger, Katrine B Hansen, Viggo B Kristiansen, Steen Larsen, Jens Juul Holst, Filip K Knop

24 Citations (Scopus)

Abstract

Background: Laparoscopic adjustable gastric banding (LAGB) provides weight loss in obese individuals and is associated with improved glucose homeostasis and resolution of type 2 diabetes. However, in most available reports, potentially inappropriate methodology has been applied when measuring the impact of LAGB on glucose intolerance. In order to clarify the applicability of the diagnostic 75 g-oral glucose tolerance test (OGTT) to measure the effect of LAGB on glucose metabolism, we investigated the effect of LAGB on gastric emptying for liquids as well as pancreatic and incretin hormone responses. Methods: Eight obese patients (three with normal glucose tolerance, three with impaired glucose tolerance, and two with type 2 diabetes; age 47.5±1.1 years (mean±SEM); body mass index 44±1 kg/m²; HbA ₁c 6.2±0.4%) underwent a 75 g-oral glucose tolerance test with 1 g acetaminophen before and ~6 weeks after LAGB. Results: A small weight reduction was seen after LAGB (125±8 vs. 121±8 kg, P=0.014). No differences in determinants of gastric emptying were observed before and after LAGB (area under the serum acetaminophen curve 10.1±0.6 vs. 9.8±0.5 mM×4 h, P=0.8; peak acetaminophen concentration 62±3 vs. 61±3 μM, P=0.8; acetaminophen peak time 98±6 vs. 100±6 min, P=0.9). No differences in plasma glucose, insulin, C-peptide, glucagon, glucose-dependent insulinotropic polypeptide, or glucagon-like peptide-1 responses to the OGTT were observed before as compared to after LAGB. Conclusions: OGTT can be used to evaluate glucose tolerance in obese patients before and after LAGB without bias from changes in gastric emptying. LAGB has no direct impact on incretin hormone secretion.

Original language	English
Journal	Obesity Surgery
Volume	21
Issue number	5
Pages (from-to)	625-32
Number of pages	8
ISSN	0960-8923
DOIs	https://doi.org/10.1007/s11695-011-0362-9
Publication status	Published - May 2011

Keywords

Acetaminophen
Adult
C-Peptide
Female
Gastric Emptying
Gastric Inhibitory Polypeptide
Gastroplasty
Glucagon-Like Peptide 1
Glucose Intolerance
Glucose Tolerance Test
Humans
Insulin
Laparoscopy
Male
Middle Aged

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s11695-011-0362-9

Cite this

@article{575551f46a7c433294513222f4159501,

title = "Gastric emptying of orally administered glucose solutions and incretin hormone responses are unaffected by laparoscopic adjustable gastric banding",

abstract = "Background: Laparoscopic adjustable gastric banding (LAGB) provides weight loss in obese individuals and is associated with improved glucose homeostasis and resolution of type 2 diabetes. However, in most available reports, potentially inappropriate methodology has been applied when measuring the impact of LAGB on glucose intolerance. In order to clarify the applicability of the diagnostic 75 g-oral glucose tolerance test (OGTT) to measure the effect of LAGB on glucose metabolism, we investigated the effect of LAGB on gastric emptying for liquids as well as pancreatic and incretin hormone responses. Methods: Eight obese patients (three with normal glucose tolerance, three with impaired glucose tolerance, and two with type 2 diabetes; age 47.5±1.1 years (mean±SEM); body mass index 44±1 kg/m2; HbA 1c 6.2±0.4%) underwent a 75 g-oral glucose tolerance test with 1 g acetaminophen before and ~6 weeks after LAGB. Results: A small weight reduction was seen after LAGB (125±8 vs. 121±8 kg, P=0.014). No differences in determinants of gastric emptying were observed before and after LAGB (area under the serum acetaminophen curve 10.1±0.6 vs. 9.8±0.5 mM×4 h, P=0.8; peak acetaminophen concentration 62±3 vs. 61±3 μM, P=0.8; acetaminophen peak time 98±6 vs. 100±6 min, P=0.9). No differences in plasma glucose, insulin, C-peptide, glucagon, glucose-dependent insulinotropic polypeptide, or glucagon-like peptide-1 responses to the OGTT were observed before as compared to after LAGB. Conclusions: OGTT can be used to evaluate glucose tolerance in obese patients before and after LAGB without bias from changes in gastric emptying. LAGB has no direct impact on incretin hormone secretion.",

keywords = "Acetaminophen, Adult, C-Peptide, Female, Gastric Emptying, Gastric Inhibitory Polypeptide, Gastroplasty, Glucagon-Like Peptide 1, Glucose Intolerance, Glucose Tolerance Test, Humans, Insulin, Laparoscopy, Male, Middle Aged",

author = "Lotte Usinger and Hansen, {Katrine B} and Kristiansen, {Viggo B} and Steen Larsen and Holst, {Jens Juul} and Knop, {Filip K}",

year = "2011",

month = may,

doi = "10.1007/s11695-011-0362-9",

language = "English",

volume = "21",

pages = "625--32",

journal = "Obesity Surgery",

issn = "0960-8923",

publisher = "Springer",

number = "5",

}

TY - JOUR

T1 - Gastric emptying of orally administered glucose solutions and incretin hormone responses are unaffected by laparoscopic adjustable gastric banding

AU - Usinger, Lotte

AU - Hansen, Katrine B

AU - Kristiansen, Viggo B

AU - Larsen, Steen

AU - Holst, Jens Juul

AU - Knop, Filip K

PY - 2011/5

Y1 - 2011/5

N2 - Background: Laparoscopic adjustable gastric banding (LAGB) provides weight loss in obese individuals and is associated with improved glucose homeostasis and resolution of type 2 diabetes. However, in most available reports, potentially inappropriate methodology has been applied when measuring the impact of LAGB on glucose intolerance. In order to clarify the applicability of the diagnostic 75 g-oral glucose tolerance test (OGTT) to measure the effect of LAGB on glucose metabolism, we investigated the effect of LAGB on gastric emptying for liquids as well as pancreatic and incretin hormone responses. Methods: Eight obese patients (three with normal glucose tolerance, three with impaired glucose tolerance, and two with type 2 diabetes; age 47.5±1.1 years (mean±SEM); body mass index 44±1 kg/m2; HbA 1c 6.2±0.4%) underwent a 75 g-oral glucose tolerance test with 1 g acetaminophen before and ~6 weeks after LAGB. Results: A small weight reduction was seen after LAGB (125±8 vs. 121±8 kg, P=0.014). No differences in determinants of gastric emptying were observed before and after LAGB (area under the serum acetaminophen curve 10.1±0.6 vs. 9.8±0.5 mM×4 h, P=0.8; peak acetaminophen concentration 62±3 vs. 61±3 μM, P=0.8; acetaminophen peak time 98±6 vs. 100±6 min, P=0.9). No differences in plasma glucose, insulin, C-peptide, glucagon, glucose-dependent insulinotropic polypeptide, or glucagon-like peptide-1 responses to the OGTT were observed before as compared to after LAGB. Conclusions: OGTT can be used to evaluate glucose tolerance in obese patients before and after LAGB without bias from changes in gastric emptying. LAGB has no direct impact on incretin hormone secretion.

AB - Background: Laparoscopic adjustable gastric banding (LAGB) provides weight loss in obese individuals and is associated with improved glucose homeostasis and resolution of type 2 diabetes. However, in most available reports, potentially inappropriate methodology has been applied when measuring the impact of LAGB on glucose intolerance. In order to clarify the applicability of the diagnostic 75 g-oral glucose tolerance test (OGTT) to measure the effect of LAGB on glucose metabolism, we investigated the effect of LAGB on gastric emptying for liquids as well as pancreatic and incretin hormone responses. Methods: Eight obese patients (three with normal glucose tolerance, three with impaired glucose tolerance, and two with type 2 diabetes; age 47.5±1.1 years (mean±SEM); body mass index 44±1 kg/m2; HbA 1c 6.2±0.4%) underwent a 75 g-oral glucose tolerance test with 1 g acetaminophen before and ~6 weeks after LAGB. Results: A small weight reduction was seen after LAGB (125±8 vs. 121±8 kg, P=0.014). No differences in determinants of gastric emptying were observed before and after LAGB (area under the serum acetaminophen curve 10.1±0.6 vs. 9.8±0.5 mM×4 h, P=0.8; peak acetaminophen concentration 62±3 vs. 61±3 μM, P=0.8; acetaminophen peak time 98±6 vs. 100±6 min, P=0.9). No differences in plasma glucose, insulin, C-peptide, glucagon, glucose-dependent insulinotropic polypeptide, or glucagon-like peptide-1 responses to the OGTT were observed before as compared to after LAGB. Conclusions: OGTT can be used to evaluate glucose tolerance in obese patients before and after LAGB without bias from changes in gastric emptying. LAGB has no direct impact on incretin hormone secretion.

KW - Acetaminophen

KW - Adult

KW - C-Peptide

KW - Female

KW - Gastric Emptying

KW - Gastric Inhibitory Polypeptide

KW - Gastroplasty

KW - Glucagon-Like Peptide 1

KW - Glucose Intolerance

KW - Glucose Tolerance Test

KW - Humans

KW - Insulin

KW - Laparoscopy

KW - Male

KW - Middle Aged

U2 - 10.1007/s11695-011-0362-9

DO - 10.1007/s11695-011-0362-9

M3 - Journal article

C2 - 21287292

SN - 0960-8923

VL - 21

SP - 625

EP - 632

JO - Obesity Surgery

JF - Obesity Surgery

IS - 5

ER -

Gastric emptying of orally administered glucose solutions and incretin hormone responses are unaffected by laparoscopic adjustable gastric banding

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this